A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Idiopathic Inflammatory Myopathy
Systemic Sclerosis
Rheumatoid Arthritis

Interventions

DRUG: CC-97540
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Tocilizumab

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Collaborators

[object Object]